Response to imatinib in vaginal melanoma with KIT p.Val559Gly mutation previously treated with nivolumab, pembrolizumab and ipilimumab

J Dermatol. 2019 Jun;46(6):e203-e204. doi: 10.1111/1346-8138.14763. Epub 2019 Jan 7.

Authors

Takayoshi Komatsu-Fujii¹, Motoo Nomura², Atsushi Otsuka¹, Yoshihiro Ishida¹, Keitaro Doi², Shigemi Matsumoto², Manabu Muto², Kenji Kabashima¹

Affiliations

¹ Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
² Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

PMID: 30614559
DOI: 10.1111/1346-8138.14763

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Drug Resistance, Neoplasm / drug effects
Drug Resistance, Neoplasm / genetics
Female
Humans
Imatinib Mesylate / pharmacology
Imatinib Mesylate / therapeutic use*
Ipilimumab / pharmacology
Ipilimumab / therapeutic use
Melanoma / diagnostic imaging
Melanoma / genetics
Melanoma / therapy*
Nivolumab / pharmacology
Nivolumab / therapeutic use
Off-Label Use
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins c-kit / genetics*
Treatment Outcome
Vagina / surgery
Vaginal Neoplasms / diagnostic imaging
Vaginal Neoplasms / genetics
Vaginal Neoplasms / therapy*

Substances

Antibodies, Monoclonal, Humanized
Ipilimumab
Protein Kinase Inhibitors
Nivolumab
Imatinib Mesylate
pembrolizumab
KIT protein, human
Proto-Oncogene Proteins c-kit